Innate Pharma S.A.
IPHANASDAQHealthcare● Active
$1.76
+$0.05(+2.92%)
Market Cap$165269787
P/E Ratio—
52W High$2.63
52W Low$1.17
Innate Pharma S.A. (IPHA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IPHA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.35
Est. -$0.16 · -116.4%
Revenue
$0.00B
Est. $0.01B · -16.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
IPHA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 17, 2026 | -$0.33 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.16 | -$0.35 | -116.4% | $0.00B | $0.01B | -16.1% |
| ▼ Q3 FY2025 | Sep 17, 2025 | -$0.14 | -$0.29 | -106.5% | $0.01B | $0.00B | +192.0% |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.27 | -$0.32 | -18.3% | $0.00B | $0.02B | -98.4% |
| ▲ Q4 FY2020 | Nov 17, 2020 | -$0.34 | -$0.15 | +56.1% | $0.04B | $0.04B | +4.0% |
| ▼ Q2 FY2020 | May 12, 2020 | -$0.43 | -$0.59 | -36.6% | $0.02B | $0.02B | +3.5% |
| — Q4 FY2019 | Nov 13, 2019 | — | $0.23 | — | $0.06B | — | — |
| — Q2 FY2019 | May 15, 2019 | — | $0.36 | — | $0.08B | — | — |
Q3 FY2026
Sep 17, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.35
EPS Est.
-$0.16
EPS Surpr.
-116.4%
Revenue
$0.00B
Q3 FY2025
Sep 17, 2025Miss
EPS Actual
-$0.29
EPS Est.
-$0.14
EPS Surpr.
-106.5%
Revenue
$0.01B
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.27
EPS Surpr.
-18.3%
Revenue
$0.00B
Q4 FY2020
Nov 17, 2020Beat
EPS Actual
-$0.15
EPS Est.
-$0.34
EPS Surpr.
+56.1%
Revenue
$0.04B
Q2 FY2020
May 12, 2020Miss
EPS Actual
-$0.59
EPS Est.
-$0.43
EPS Surpr.
-36.6%
Revenue
$0.02B
Q4 FY2019
Nov 13, 2019
EPS Actual
$0.23
EPS Est.
—
EPS Surpr.
—
Revenue
$0.06B
Q2 FY2019
May 15, 2019
EPS Actual
$0.36
EPS Est.
—
EPS Surpr.
—
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q1 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q4 FY2025 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q2 FY2025 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Q2 FY2024 | $-0.33 | $-0.33 | $-0.33 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -116.4% | $1.36 | $1.32 | -2.94% |
| ▼ Q3 FY2025 | Sep 17, 2025 | -106.5% | $2.08 | $2.05 | -1.44% |
| ▼ Q2 FY2025 | May 12, 2025 | -18.3% | $2.44 | $2.32 | -4.92% |
| ▲ Q4 FY2020 | Nov 17, 2020 | +56.1% | $4.59 | $4.79 | +4.36% |
| ▼ Q2 FY2020 | May 12, 2020 | -36.6% | $8.20 | $7.67 | -6.46% |
| — Q4 FY2019 | Nov 13, 2019 | — | $6.48 | $6.28 | -3.09% |
| — Q2 FY2019 | May 15, 2019 | — | No price data | $6.05 | — |
| — Q2 FY2018 | Jun 30, 2018 | — | No price data | $6.05 | — |
Q2 FY2026-2.94%
Report Date
May 13, 2026
EPS Beat/Miss
-116.4%
Price Before
$1.36
Price After
$1.32
Q3 FY2025-1.44%
Report Date
Sep 17, 2025
EPS Beat/Miss
-106.5%
Price Before
$2.08
Price After
$2.05
Q2 FY2025-4.92%
Report Date
May 12, 2025
EPS Beat/Miss
-18.3%
Price Before
$2.44
Price After
$2.32
Q4 FY2020+4.36%
Report Date
Nov 17, 2020
EPS Beat/Miss
+56.1%
Price Before
$4.59
Price After
$4.79
Q2 FY2020-6.46%
Report Date
May 12, 2020
EPS Beat/Miss
-36.6%
Price Before
$8.20
Price After
$7.67
Q4 FY2019-3.09%
Report Date
Nov 13, 2019
EPS Beat/Miss
—
Price Before
$6.48
Price After
$6.28
Q2 FY2019—
Report Date
May 15, 2019
EPS Beat/Miss
—
Price Before
—
Price After
$6.05
Q2 FY2018—
Report Date
Jun 30, 2018
EPS Beat/Miss
—
Price Before
—
Price After
$6.05
Avg Beat Reaction+4.36%
Avg Miss Reaction-3.94%
Beat Rate1 / 8 quarters
Largest Move-6.46% (Q2 FY2020)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IPHA ends December
Innate Pharma S.A. (IPHA) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.35 — missing the analyst consensus of $-0.16 by -116.4%. The next IPHA earnings date is expected around September 1, 2026.
Each quarter, investors track IPHA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IPHA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IPHA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IPHA earnings · 5 questionsInnate Pharma S.A.'s next earnings report is expected around September 1, 2026. IPHA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IPHA historically reports after market close (AMC).
IPHA earnings datewhen is IPHA earningsIPHA next earnings datewhen does IPHA report earningsIPHA earnings calendar
▸ Source: FMP · Innate Pharma S.A. SEC filings · US GAAP · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026